Erdafitinib and Pamprin Cramp Formula

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels. Serum phosphate levels are used as a guide to the initial dosage increase between 14 to 21 days after initiating erdafitinib therapy, as well as dose modification during therapy. In clinical trials with erdafitinib, hyperphosphatemia (all grades) was reported as an adverse event in 76% of erdafitinib-treated patients, with a median onset time of 20 days, requiring phosphate binder therapy in 32% of patients. During these clinical trials, agents that are known to increase serum phosphate levels (e.g., potassium phosphate supplements, vitamin D supplements, antacids, phosphate-containing enemas or laxatives, and medications known to have phosphate as an excipient) were prohibited during clinical trials with erdafitinib unless no alternative existed; however, phosphate binders were permitted to treat increases in serum phosphate levels. MANAGEMENT: The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended. To minimize risk of hyperphosphatemia, there is a recommendation for patients to restrict phosphate intake to 600 to 800 mg daily. The manufacturer recommends monthly phosphate level monitoring during erdafitinib treatment along with dose adjustment guidelines based on serum phosphate levels included in its product labeling. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.

MONITOR CLOSELY: Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels. Serum phosphate levels are used as a guide to the initial dosage increase between 14 to 21 days after initiating erdafitinib therapy, as well as dose modification during therapy. In clinical trials with erdafitinib, hyperphosphatemia (all grades) was reported as an adverse event in 76% of erdafitinib-treated patients, with a median onset time of 20 days, requiring phosphate binder therapy in 32% of patients. During these clinical trials, agents that are known to increase serum phosphate levels (e.g., potassium phosphate supplements, vitamin D supplements, antacids, phosphate-containing enemas or laxatives, and medications known to have phosphate as an excipient) were prohibited during clinical trials with erdafitinib unless no alternative existed; however, phosphate binders were permitted to treat increases in serum phosphate levels.

MANAGEMENT: The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended. To minimize risk of hyperphosphatemia, there is a recommendation for patients to restrict phosphate intake to 600 to 800 mg daily. The manufacturer recommends monthly phosphate level monitoring during erdafitinib treatment along with dose adjustment guidelines based on serum phosphate levels included in its product labeling.

Erdafitinib

Generic Name: erdafitinib

Brand name: Balversa

Synonyms: n.a.

What is Erdafitinib?

Pamprin Cramp Formula

Generic Name: acetaminophen / magnesium salicylate / pamabrom

Brand name: Pamprin Cramp Formula

Synonyms: n.a.

What is Pamprin Cramp Formula?